Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6413091 | 0.86 | MAPT (0.48) | MAPTHTTMEN1KMT2ALMNA | |
| SCHEMBL6408513 | 0.84 | MAPT (0.57) | MAPTGAAHTTMEN1KMT2A | |
| SCHEMBL2418211 | 0.83 | POLB (0.54) | MAPTGAAMEN1KMT2APOLB | |
| SCHEMBL6414576 | 0.81 | KDR (0.50) | MAPTHTTLMNASMN1; SMN2HPGD | |
| SCHEMBL2417780 | 0.81 | MEN1 (0.46) | MAPTGAAHTTMEN1KMT2A | |
| SCHEMBL2416763 | 0.79 | POLB (0.46) | MAPTHTTMEN1KMT2ALMNA | |
| SCHEMBL6417097 | 0.78 | KDM4E (0.52) | GAALMNATP53SMN1; SMN2HPGD | |
| SCHEMBL2412727 | 0.78 | MEN1 (0.45) | MAPTHTTMEN1KMT2ALMNA | |
| SCHEMBL2420095 | 0.78 | MEN1 (0.47) | MAPTHTTMEN1KMT2ALMNA | |
| SCHEMBL2421425 | 0.78 | KMT2A (0.51) | MAPTGAAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026984-A1 | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026984-A1 | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products | TPMT, PARK7, PRNP | MAPT 8/4885GAA 1366/4885HTT 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.